Monoclonal antibody · developed by Kodiak Sciences
Tarcocimab tedromer (KSI-301) is an antibody biopolymer conjugate that binds vascular endothelial growth factor (VEGF) and is being studied for wet age-related macular degeneration and non-proliferative diabetic retinopathy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06556368 | Phase 3 | Wet Age-related Macular Degeneration | Active not recruiting | KOD |
| NCT05066230 | Phase 3 | Non-proliferative Diabetic Retinopathy | Terminated | KOD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Wet Age-related Macular DegenerationNon-proliferative Diabetic Retinopathy
See KOD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KOD catalysts and pipeline →